tbuckley/cabot-search huggingface dataset:
Reliability of data collection for the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multi-center outcomes database: A methodological approach
Authors: M. E. Kho, E. M. Lepisto, J. C. Niland, A. terVeer, A. S. LaCasce, J. W. Friedberg, J. C. Weeks
Journal: Journal of Clinical Oncology (2007)

6525 Background: Clinical trials and outcomes studies often rely on non-physicians to abstract complex data from medical records. We assessed the reliability of chart abstraction among personnel groups in a multi-center outcomes study of indolent/aggressive NHL treated in NCCN centers. Methods: We developed 20 standardized charts of patients with newly-diagnosed NHL. Raters included 6 Clinical Research Associates from participating sites (CRAs), 3 project staff who conduct CRA training, and 3 medical oncologists. Raters each received a set of standardized charts, detailed instructions and training on a sample chart and abstracted all charts independently. We assessed reliability on 5 variables: MD-reported and rater-determined disease stage; International Prognostic Index (IPI- low-low intermediate, intermediate-high, high); Charlson comorbidity index score; and presence of any item from the Charlson index. We used intraclass correlation coefficients (ICCs) to calculate reliability. We considered coefficients from 0–0.20 ‘slight’, 0.21–0.40 ‘fair’, 0.41–0.60 ‘moderate’, 0.61–0.80 ‘substantial’ and &gt;0.80 ‘almost perfect’(1). Results: Overall reliability was “almost perfect/substantial” for MD-reported stage, rater-determined stage, and IPI, but only “moderate” for the 2 Charlson-based comorbidity measures (Table). Reliability varied by rater group; no rater group was consistently more reliable than others. Conclusions: Trained CRAs abstracted key clinical variables with a very high degree of reliability, and performed at a level similar to study trainers and oncologists. Elements of the Charlson index were less reliable than other data types, possibly due to inherent ambiguity in the index itself. Use of trained CRA staff is reasonable to collect stage and IPI scores in a multi-center outcomes study, however abstracted Charlson scores should be interpreted with caution. (1)Biometrics. 1977. 33:159–74. No significant financial relationships to disclose. [Table: see text]
Abstract 12685: Hospital Variation in Adherence to Secondary Prevention Medications After Acute Myocardial Infarction
Authors: William T Wang, Robin Mathews, Lisa A McCoy, Laine Thomas, Rashmee Shah, Murtuza J Ali, Eric D Peterson, Tracy Y Wang
Journal: Circulation (2015)

Background: Hospital transition of care practices may influence patient adherence to secondary prevention medications post-discharge. We assessed inter-hospital variation in 90-day post-MI medication adherence and its association with downstream patient outcomes. Methods: We linked 19,704 post-acute MI patients &gt;65 years discharged alive from 459 hospitals in ACTION Registry-GWTG to Medicare data. Adherence was defined as ≥80% proportion of days covered using Part D prescription fill data. Based on the distribution of odds ratios, hospitals were divided into high (&gt;75 th percentile), medium, or low (&lt;25% percentile) adherence. We used Cox regression to compare 2-year MACE outcomes (death, MI, stroke, or non-staged revascularization) after adjusting for hospital case mix differences. Results: By 90 days post-MI, 68% of patients were adherent to discharge-prescribed beta-blocker therapy, 63% to statins, 64% to ACEI/ARBs, and 72% to thienopyridines. There was significant inter-hospital variation in 90-day adherence (p&lt;0.001), the probability of which varied the least for ACE-I/ARBs, and most for beta-blockers (Figure). Hospitals with medium medication adherence had lower unadjusted 2-year MACE risk than hospitals with low adherence, but this did not reach statistical significance after adjusting for differences in patient case mix (unadjusted 33.4% vs. 37.3%, adjusted HR 0.94, 95% CI 0.86-1.02); however, high medication adherence hospitals had significantly lower unadjusted (29.9%) and adjusted risk of MACE (HR 0.90, 95% CI 0.82-0.98). Conclusion: Patient adherence to secondary prevention medications varied markedly across U.S. hospitals. Discharge from hospitals with higher adherence rates was associated with lower risks of MACE. Our results suggest that the development of collaborative initiatives between healthcare providers and patients to improve post-discharge medication adherence may enhance longitudinal patient outcomes.
Pituitary Mammotropic Tumor in Rats: Evidence for a Dosage Effect on Organ Weight and Liver Drug Metabolism&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: J T Wilson
Journal: JNCI Journal of the National Cancer Institute (1969)

Changes in rat organ weight and liver drug metabolism found in rats with a pituitary mammotropic tumor (MtT-F4, here designated as MtT) may be related to the amount of MtT injected. To test this hypothesis, various doses of the tumor were implanted in male rats and allowed to grow for 2–50 days. An increase in liver, adrenal, and kidney weight and a decrease in testis weight were related to the amount of MtT injected when these parameters were studied 50 days after the injection of 250 mg or less of MtT. A dose of MtT equivalent to 250 mg produced the maximum changes in rat liver, adrenal, and testis weight for each period studied. A progressive decrease in the hepatic metabolism of hexobarbital and aminopyrine was noted with increased doses of MtT when studied from 9–25 days after tumor injection. However, a low level of liver drug metabolism which was unrelated to high (over 62.5 mg) doses of MtT was noted after 25–30 days of tumor growth. These results suggest that a) changes in organ weight and liver drug biotransformation are related to increased amounts of factors (possibly somatotropic hormone, adrenocorticotropin, and lactogenic hormone) produced by the MtT, and b) a dose of MtT (250 mg) may be injected which will give maximal changes in organ weight and hepatic drug metabolic activity for a specified period of MtT growth.
Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-RUNX1T1 Fusion Quantification On Genomic DNA
Authors: Nicolas Duployez, Aline Renneville, Olivier Nibourel, Alice Marceau-Renaut, Nathalie Helevaut, Aurélie Caillault, Celine Villenet, Karine Celli-Lebras, Nicolas Boissel, Eric Jourdan, Herve Dombret, Martin Figeac, Claude Preudhomme
Journal: Blood (2013)
The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia.
Authors: G K Rivera
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.2.191 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3276820 The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia. G K RiveraxG K RiveraSearch for articles by this author Show More St. Jude Children's Research Hospital, Memphis. https://doi.org/10.1200/JCO.1988.6.2.191 First Page PDF © 1988 by American Society of Clinical Oncology
Oestrogen therapy and endometrial cancer. (Letter)
Authors: Utian Wh
Journal: BMJ (1977)

The most controversial issue related to prolonged estrogen therapy is the possible relationship of this therapy to the etiology and pathogenesis of breast and uterine cancer.  The imprecise nature of the relevant data does not allow full definition of the rish.  To maintain proper perspective smoking 20 cigarettes a day increases the risk of death from lung cancer 17 times;  the risk from estrogens is less than that.  There is no controversy over the use of estrogens for short-term relief of menopausal symptoms.  The Mulley and Mitchell paper referred to was opinion based on no direct research and an inadequate knowledge of the literature.  The early symptoms of estrogen dificiency hot flushes and atrophic vaginitis respond to short-term estrogen therapy which in addition provides a mental tonic effect.  It is not justifiable to withhold such therapy from the normal informed patient requesting it provided no contraindications exist.  The patient should be reevaluated at frequent intervals and the proper selection of drug dosage and therepeutic regimen administered.  This can be accomplished including research through a menopause clinic.
Myeloid Malignancies With Isochromosome 17q Harbor Frequently Mutations In ASXL1, SETBP1, and SRSF2 - This Distinct Genotype Presents With Various Morphological Phenotypes
Authors: Manja Meggendorfer, Tamara Alpermann, Claudia Haferlach, Elisabeth Sirch, Wolfgang Kern, Torsten Haferlach, Susanne Schnittger
Journal: Blood (2013)
Evaluation of the response for gefitinib in patients with non-small cell lung cancer (NSCLC) using FDG-PET scan
Authors: T. Fujishita, T. Kashii, T. Miwa, H. Oda, M. Kobayashi, K. Nomura, H. Seto, I. Matsunari, K.-I. Hisada
Journal: Journal of Clinical Oncology (2004)

9703 Background: Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scan is reported as useful and accurate nuclear medicine method for diagnosis of malignancy/benign, staging, metastasis and recurrence in primary lung cancer. Gefitinib (Iressa) is an orally active, selective EGFR-tyrosine kinase inhibitor that blocks signal transduction pathways implicated in proliferation and survival of cancer cells. Phase II trial to evaluate objective tumor response rate and safety of ZD1839 was operated worldwide in patients with previously treated NSCLC. In this study, we aimed to evaluate the usefulness of FDG-PET scan for the response of gefitinib in NSCLC. Method: Fourteen patients of recurrent or chemotherapy refractory NCSLC administered 250 mg/day of gefitinib were analyzed. Twelve patients treated with gefitinib evaluated the response using conventional CT scan were compared with FDG-PET scan at a time. Two patients diagnosed for BAC (bronchioloalveolar carcinoma) could not be analyzed because of no FDG uptake before treatment. The response of FDG-PET scan was analyzed with standard uptake value (SUV) change and visualized evaluation by 2 pulmonary oncologists. Results: Four PRs, 8 SDs and 2 PD were evaluated with CT scan. Eight of 12 (66.7%) patients had the same result with both methods. Four SDs (33.3%) evaluated with CT scan had a result of PR in FDG-PET scan. Two of these patients were reevaluated to PR with CT scan in 4–8 weeks later. Conclusions: These results suggest that the response of FDG-PET scan was earlier than that of CT scan in patients treated with gefitinib. FDG-PET scan might be used in routine practice to evaluate the chemotherapeutic response of molecular target agents including gefitinib in primary lung cancer. Large prospective study with precise design is necessary. No significant financial relationships to disclose.
Evaluating psychosocial and belief differences in a diverse racial and socioeconomic cancer population.
Authors: B. N. Polite, D. M. Smith, M. Ray, F. J. Hlubocky, O. I. Olopade, C. Daugherty, S. J. Gehlert
Journal: Journal of Clinical Oncology (2010)

6036 Background: Cancer outcomes differ significantly by race and socioeconomic status. Psychosocial and belief differences may mediate these disparities but are poorly studied. Methods: Breast, colon, and lung cancer patients (pts) presenting for their first oncology appointment completed a self-administered survey utilizing previously validated instruments regarding psychosocial and belief factors (e.g., God LOC, HADS). Results were analyzed by self-identified race and income. Results: 104 African American (AA-37%) and 176 white (w-63%) new visit oncology pts with breast (52%) colon (16%) and lung (32%) cancer enrolled. Median age: AA-62 (31-93), W-58 (31-83). 22% of the pts had incomes <20K and 49% >60K. AA were more likely in the lower income group (47% vs. 8%) but 20% had incomes>60K. No significant differences by diagnosis or stage seen. Main outcomes are in the Table. Apparent racial differences in social support, health literacy, and cancer knowledge were mediated by income. Differences in anxiety, depression, and the role of God remained after adjustments for income. For example, AA more likely felt God was in control of their cancer (66% vs. 32%). There were no overall differences in trust scores; however, AA more likely believed clinic staff served white pts before AA and Hispanic pts (27% vs. 5%). Conclusions: Clear psychosocial and belief differences exist by race and class. For race, the importance of God in the cancer decision-making process must be openly acknowledged and anxiety and depression must be addressed. For class, social support, health literacy, and cancer knowledge dominate. Differences in trust are often assumed, but were not dominant in this study. Underexamined areas of bias, such as clinic staff, should be addressed. Continued work in this study will link these factors to chemotherapy adherence and clinical trial participation. AA W p value (unadjusted) p value (adjusted-income) Social support (std mean) 78 83 0.015 0.45 Anxiety (%HADS > 10) 2% 17% <0.001 <0.001 Depression (% HADS > 10) 1% 9% 0.02 0.01 MD distrust (std mean) 24 25 0.57 - HS distrust (std mean) 30 28 0.39 - God LOC (std mean) 52 38 0.002 0.02 Health literacy (mean-higher worse) 4.1 3.5 <0.001 0.2 Air and cancer (% true) 23% 16% 0.03 0.46 No significant financial relationships to disclose.
Abstract 11522: Reduction of Cardiac Arrests: The Experience of a Novel Service Centric Rapid Response Team
Authors: Adam M Noyes, Dadong Li, Daniel Madison, Bernadette Madison, Theodore Madison, Jason Gluck, Jeffery Kluger
Journal: Circulation (2013)

Background:  The impact of rapid response teams (RRTs) on number of cardiac arrests (CAs) is unclear. We hypothesize that a novel, service centric (SC), budget neutral RRT model can impact the incidence of CA by bringing critical care expertise to the bedside of a deteriorating patient. The SC RRT model includes a medical provider from the medical/surgical service to which the patient is admitted (cardiology, medicine, general surgery, etc.), a critical care RN and a respiratory therapist.   Methods:  A retrospective analysis was performed on prospectively collected data on adults in a 867-bed tertiary care hospital for the years 2007 to 2012. The SC RRT program started on 12/23/2007 in Cardiology and expanded hospital wide during 2008/2009, maturing at 10 teams. CA rate was adjusted for hospital care days. Pairwise comparisons of CA rate between 3-time periods were performed for ICU, Non-ICU and combined ICU/Non-ICU patients.   Results:  Of the total 1,140,233 hospital care days analyzed from 2007 through 2012, 745 patients had CA. The overall CA rate was significantly higher in 2007 than in 2008/09 and 2010/12 (0.84 vs 0.59 and 0.84 vs 0.64 per 1000 care days, p   Conclusions:  A novel budget neutral service centric RRT program is associated with a reduction in the overall incidence of CAs in both ICUs and non-ICUs. A potential explanation for these observations is earlier intervention in the care of unstable patients by an expanded group of expert caregivers.
Targeted therapy with AP 12009 in recurrent or refractory glioblastoma patients: Results of a phase Iib study
Authors: U. Bogdahn, P. Hau, V. Olyushin, A. K. Mahapatra, V. Parfenov, N. K. Venkataramana, H. Wassmann, S. Ludwig, H. Heinrichs, K. H. Schlingensiepen
Journal: Journal of Clinical Oncology (2008)

2018 Background: High-grade gliomas (HGG) show an overexpression of the immunosuppressor transforming growth factor beta 2 (TGF-beta 2). AP 12009 is a TGF-beta 2 specific phosphorothioate, which has been successfully tested in phase I/II studies in patients with recurrent or refractory HGG. Methods: The phase IIb study G004 was an international, open-label, randomized, active-controlled, dose-finding study. The main objective of the study was to compare two doses of AP 12009 (10 μM=AP-10 or 80 μM=AP-80) and standard chemotherapy control (TMZ or PCV if TMZ had already failed) with regard to response rate, survival, and safety. Patients with histopathologically confirmed recurrent or refractory HGG (WHO grades III and IV, N=145) were randomized into 3 treatment groups. AP 12009 was administered intratumorally by convection-enhanced delivery with up to 11 treatment cycles (7-d-on, 7-d-off/cycle). Results: Here we report on patients with recurrent or refractory GBM (WHO grade IV, AA patients see separate abstract). Dose finding was achieved as efficacy and safety results for the AP-10 group tended to be better than those for the AP-80 group. AP 12009 was well tolerated. Comparable hazard ratios for survival were seen for the 3 treatment groups. In the 2 AP 12009 groups more survivors were observed after 1.5 and 2 years than in the control group. After 12 months, the best overall response rate (CR+PR) as well as the best tumor control rate (CR+PR+SD) was observed in the AP-10 group. Tumor responses in the AP 12009 treatment groups by far exceeded active treatment. Conclusions: Although the prognostic factor age was highest in the AP-10 group, this study showed a trend towards better efficacy and safety of the lower dose of AP 12009. Furthermore, this is the first specific molecular targeted agent in malignant glioma to show equal efficacy compared to TMZ chemotherapy. A phase III study of AP 12009 in combination with standard antitumor therapeutics as first-line therapy is planned for 2008. Treatment group AP-10, N=28 AP-80, N=34 Control(TMZ, N=28 /PCV, N=5) Median age (years) 56.5 45.0 52.0 SAEs drug-related (N) 0 3 1 Overall response rate (CR + PR at 12 months, %) 7 0 3 Tumor control rate (CR + PR + SD at 12 months, %) 11 6 9 CR=complete response, PR=partial response, SD=stable disease Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Antisense Pharma Antisense Pharma GmbH Antisense Pharma Antisense Pharma
Participative design of a support questionnaire for the process of diagnosing anorexia-caquexia syndorme (ACS) in cancer patients
Authors: V. Valentín, A. Casas, J. Carulla, C. Camps, M. Gonzalez Baron, J. Lizón, J. Sanz, L. Iglesias, A. Covas, S. Pisa
Journal: Journal of Clinical Oncology (2007)

19662 Background: Early treatment of the anorexia-cachexia syndrome (ACS) provides a significant benefit for cancer patients, hence the need for early diagnosis. Currently available tools are complex, hampering their systematic application in clinical practice and treatment does not begin until moderate-to-severe states of malnutrition are reached. After holding 20 workshops between 2003–2005 involving about 150 Spanish oncologists, it was concluded that the ACS diagnosis should be based on questionnaires, anthropometric assessment and analytical determination, hence the need for design a brief and efficient questionnaire to support the process of diagnosing ACS in cancer patients. Methods: Between February and June 2006, 9 working sessions were held and 123 oncologists consulted to assess the symptoms and diagnostic tests required for the evaluation of ACS. In all sessions a preliminary presentation was given on the conclusions of the workshops held over the previous two years, followed by a structured discussion that was facilitated by a moderator using the Metaplan work method. Results: Questions achieving a consensus of over 75% were deemed as essential. Included among the questions to be answered by the patients are: anorexia (79.7%), dysphagia (78.9%) and vomiting/nausea (79.7%). The physician’s set of questions include: evolution of body weight determined by weight loss &gt;10% (94.3%); stage of the disease (80.5%), considering stage IV to be an alert sign of ACS; the location of the neoplasia (78.9%), with head and neck, esophagus, pancreas, biliary ducts and stomach being the most prevalent neoplasia locations among these patients and albumin level (77.2%), being suspected ACS diagnosis on 2.1 mg/dl or less. It was agreed that the questionnaire should be a simple tool, phrased in easy-to- understand language and formulated with short (92%) and few (85%)questions and to keep the format simple, making it easier to fill in (36.5%). The inclusion of closed “Yes/No” type answers was regarded positively. Conclusions: The proposed ACS diagnosis questionnaire meets the expectations set at the start of the project. We are currently carrying out a validation process in order to ensure its reproducibility. No significant financial relationships to disclose.
A multicenter phase I/II study of gemcitabine and personalized peptide vaccination combination therapy for metastatic pancreatic cancer patients
Authors: H. Yanagmoto, S. Satoi, T. Mine, K. Tanaka, A. Yamada, M. Oka, K. Itoh
Journal: Journal of Clinical Oncology (2008)

4633 Background: The present multicenter phase I/II study was conducted to confirm the efficacy and toxicity of immunochemotherapy for metastatic pancreatic cancer. Methods: HLA-A2 or A24 positive patients with histologically or cytologically proven pancreatic adenocarcinoma with at least one measurable metastatic lesion were eligible for the study. Other eligibility criteria included: age of 20–80 years, ECOG performance status (PS) of 0 or 1, and adequate organ function. Gemcitabine was given intravenously at a dose of 1,000 mg/m2 over 30 min once a week for three weeks, followed by 1 week of rest, and three or four peptides that had been positive for pre-existing peptide-specific immune responses in the circulation (personalized peptide vaccine) were injected subcutaneously in the femoral area once a week. The objective response rate was assessed according to RECIST. Results: Twenty patients from 2 institutions were enrolled in this study. The median age was 63 years (range: 41–80 years). The PS was 0 in 10 patients (50%) and 1 in 10 patients (50%). The efficacy and toxicity were analyzed in 20 patients who received at least one course (8 weeks) of immunochemotherapy. Although no complete response was seen, a partial response was achieved in 5 patients, resulting in an overall response rate of 25%. Eleven patients (55%) had stable disease. The median overall survival was 8.5 months with a 1-year survival rate of 33%. The major grade 3–4 toxicities using CTCAE criteria were neutropenia (25%), anemia (20%), thrombocytopenia (20%) and anorexia (5%). All 17 dermatologic reactions at the vaccination site were scored as grade 1 or 2. No treatment-related deaths occurred during the study. Augmentation of peptide-specific CTL responses in the post-vaccination peripheral blood mononuclear cells was observed in 72%, while increased titer of peptide-specific IgG antibodies was observed in the post-vaccination plasma in 78%. Conclusions: This study could be recommended for further stages of clinical trials because of safety, boosting of immune responses, and potential clinical benefits. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GreenPeptide GreenPeptide GreenPeptide Grant-in-Aid for Scientific Research from Research Center of Innovative Cancer Therapy of the 21st Century COE Program for Medical Science of Japan, Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan
Abstract 11138: Survival of US Dialysis Patients after Acute Myocardial Infarction: Is it Finally Getting Better in the Modern Treatment Era?
Authors: Gautam Shroff, Shuling Li, Charles A Herzog
Journal: Circulation (2012)

Introduction: Acute myocardial infarction (AMI) is a catastrophic event associated with dismal long-term survival in dialysis pts. We previously reported mortality rates at 1 and 2 yrs respectively...